PCM
DGX icon

Polymer Capital Management’s Quest Diagnostics DGX Stock Holding History

Polymer Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,817
Closed -$1.18M – 875
2025
Q4 		$1.18M Buy
+6,817
New +$1.24M 0.12% 206

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Polymer Capital Management's DGX Position: Q1 2026 in Review

Polymer Capital Management sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 6,817 shares — an estimated $1.18M sold.

Polymer Capital Management first reported a position in DGX in Q4 2025 and held it in 1 quarter. The position peaked at $1.18M in Q4 2025. 1,069 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Polymer Capital Management reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Polymer Capital Management sold 6,817 Quest Diagnostics shares in Q1 2026, an estimated $1.18M.
  • Polymer Capital Management first reported a position in Quest Diagnostics in Q4 2025 and held it in 1 quarter.
  • Polymer Capital Management's Quest Diagnostics position peaked at $1.18M in Q4 2025.
  • 1,069 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.